Elicio Therapeutics Amends Officer Compensation on Feb 1, 2024
Ticker: ELTX · Form: 8-K · Filed: Feb 2, 2024 · CIK: 1601485
| Field | Detail |
|---|---|
| Company | Elicio Therapeutics, Inc. (ELTX) |
| Form Type | 8-K |
| Filed Date | Feb 2, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.01, $608,400, $460,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: compensatory-arrangements, executive-compensation, corporate-governance
TL;DR
**Elicio Therapeutics just updated executive pay, signaling potential shifts in company strategy or financial health.**
AI Summary
Elicio Therapeutics, Inc. announced on February 1, 2024, that it has entered into new compensatory arrangements with certain officers, specifically regarding the terms of their employment. This matters to investors because changes in executive compensation, especially for an emerging growth company like Elicio, can signal shifts in company strategy, financial health, or efforts to retain key talent, all of which can impact future stock performance.
Why It Matters
Changes in executive compensation can reflect the company's financial strategy and its commitment to retaining key leadership, directly influencing investor confidence and future operational stability.
Risk Assessment
Risk Level: low — This filing primarily reports routine compensatory arrangements, which typically carry a low direct risk unless the terms are unusually unfavorable to shareholders.
Analyst Insight
Investors should monitor future filings for details on the specific compensatory arrangements to assess their impact on the company's financial health and executive retention, as this filing only indicates the existence of such arrangements without providing specifics.
Key Players & Entities
- Elicio Therapeutics, Inc. (company) — the registrant filing the 8-K
- February 1, 2024 (date) — date of earliest event reported
- Nasdaq Global Select Market (company) — exchange where Elicio's common stock is registered
- $0.01 (dollar_amount) — par value per share of common stock
FAQ
What was the specific date of the earliest event reported in this 8-K filing by Elicio Therapeutics, Inc.?
The earliest event reported in this 8-K filing occurred on February 1, 2024.
What is the trading symbol for Elicio Therapeutics, Inc. on the Nasdaq Global Select Market?
The trading symbol for Elicio Therapeutics, Inc. is ELTX.
What is the par value per share of Elicio Therapeutics, Inc.'s Common Stock?
The par value per share of Elicio Therapeutics, Inc.'s Common Stock is $0.01.
Is Elicio Therapeutics, Inc. considered an 'emerging growth company' according to this filing?
Yes, Elicio Therapeutics, Inc. indicates by check mark that it is an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
What is the primary item information reported in this 8-K filing?
The primary item information reported is 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'.
Filing Stats: 1,220 words · 5 min read · ~4 pages · Grade level 12.4 · Accepted 2024-02-02 08:51:10
Key Financial Figures
- $0.01 — nge on which registered) Common Stock, $0.01 par value per share ELTX The Nasdaq Glo
- $608,400 — nelly's annual base salary increased to $608,400 and his annual performance bonus opport
- $460,000 — . Dr. DeMuth's base salary increased to $460,000 and his annual performance bonus opport
Filing Documents
- angn-20240201.htm (8-K) — 31KB
- elicio-executiveseveranc.htm (EX-10.1+) — 56KB
- elicio-executiveseveranc001.jpg (GRAPHIC) — 262KB
- elicio-executiveseveranc002.jpg (GRAPHIC) — 279KB
- elicio-executiveseveranc003.jpg (GRAPHIC) — 222KB
- elicio-executiveseveranc004.jpg (GRAPHIC) — 269KB
- elicio-executiveseveranc005.jpg (GRAPHIC) — 277KB
- elicio-executiveseveranc006.jpg (GRAPHIC) — 286KB
- elicio-executiveseveranc007.jpg (GRAPHIC) — 287KB
- elicio-executiveseveranc008.jpg (GRAPHIC) — 322KB
- elicio-executiveseveranc009.jpg (GRAPHIC) — 249KB
- elicio-executiveseveranc010.jpg (GRAPHIC) — 248KB
- elicio-executiveseveranc011.jpg (GRAPHIC) — 282KB
- elicio-executiveseveranc012.jpg (GRAPHIC) — 291KB
- elicio-executiveseveranc013.jpg (GRAPHIC) — 168KB
- elicio-executiveseveranc014.jpg (GRAPHIC) — 45KB
- 0001601485-24-000013.txt ( ) — 5041KB
- angn-20240201.xsd (EX-101.SCH) — 2KB
- angn-20240201_lab.xml (EX-101.LAB) — 25KB
- angn-20240201_pre.xml (EX-101.PRE) — 13KB
- angn-20240201_htm.xml (XML) — 3KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Exhibit Description 10.1+ Executive Severance Plan. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) ____________________ + Indicates management contract or compensatory plan.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elicio Therapeutics, Inc. By: /s/ ROBERT CONNELLY Date: February 2, 2024 Robert Connelly President and Chief Executive Officer (Principal Executive Officer)